| Dr Bill Randle Hester, DC | |
|
30281 Liberty Rd, Nettleton, MS 38858-8906 | |
| (662) 963-0127 | |
| Not Available |
| Full Name | Dr Bill Randle Hester |
|---|---|
| Gender | Male |
| Speciality | Chiropractor |
| Location | 30281 Liberty Rd, Nettleton, Mississippi |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336329861 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 0475 (Mississippi) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bill Randle Hester, DC 30281 Liberty Rd, Nettleton, MS 38858-8906 Ph: (662) 963-0127 | Dr Bill Randle Hester, DC 30281 Liberty Rd, Nettleton, MS 38858-8906 Ph: (662) 963-0127 |
News Archive
Medical device pioneer Stentys announced today that the first patient has been enrolled into the ‘APPOSITION II' clinical study—a randomized trial comparing the Stentys self-expanding stent with a conventional balloon-expandable stent in AMI patients. The primary endpoint of the ‘APPOSITION II' study is stent strut apposition at day three post-procedure via extremely high-resolution OCT (optical coherence tomography) imaging.
Misys plc (LSE: MSY), the global application software and services company, today announces that it has come first in the annual Structured Products Technology Rankings. Misys was named overall top vendor in the survey of the world's leading financial institutions that create and trade cutting-edge financial products. The study recognises the key vendors and solutions in the sector and highlights the technology of choice for these institutions, Misys Summit FT.
Sinexus has changed its name to Intersect ENT. Intersect's initial focus is a bioabsorbable drug eluting stent to treat patients with chronic sinusitis, a debilitating condition that affects 37 million people each year and is more prevalent than heart disease or asthma.
New research sheds light on common pathogenic mechanisms shared by Huntington's disease (HD) and HD-like disorders. The study, published by Cell Press in the May 12, 2011, issue of the journal Neuron, uses a new transgenic mouse model for an HD-like disorder to unravel complex molecular events that drive disease pathology.
Universal Capital Management, Inc., a Wilmington, Delaware business development company that provides management and strategic growth resources to emerging growth companies, is pleased to announce that one of its holdings, iVolution Medical Systems, Inc., is preparing to launch a loan program that offers physicians easy access to working capital.
› Verified 5 days ago